

Möln dal 20 January 2020

## **Presbyterian St. Luke’s Medical Center Introduces Osseointegration Program with OPRA™ Implant System**

Presbyterian St. Luke’s Medical Center in Denver, Colorado is consistently evolving their patient care and has always been focused on advancing medicine to better serve patients. Following their history, Presbyterian St. Luke’s has started a new Osseointegration Program led by orthopaedic oncologist Dr. Daniel Lerman and plastic surgeon Dr. David Schnur. Presbyterian St. Luke’s offers state-of-the-art orthopedic care to people of all ages and Dr. Lerman’s clinical expertise in limb-sparing surgery and complex total joint reconstructions has led him and Dr. Schnur to focus on this new technology. They have taken a multidisciplinary approach to their program by bringing together a dedicated osseointegration team of surgeons, nurses and rehabilitation specialists.

Blake Pokress, Vice President of Integrum added, “Integrum is excited to work with this amazing team-oriented patient program. From the top down, they have been focused on the best of care and the addition of an osseointegration program follows their tradition of advanced medicine.”

*The information in this press release is information that Integrum AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the contact person set out below, at 09:00 CET on Jan 20, 2020.*

*Integrum AB is listed on Nasdaq First North in Stockholm. Erik Penser is the Company’s Certified Adviser.*

### **For further information contact**

María López, CEO. Mobile: +46 708 46 10 69, Email: [maria.lopez@integrum.se](mailto:maria.lopez@integrum.se)

Blake Pokress, VP North America. Mobile: +1 650-862-9302, Email: [blake.pokress@integrum.se](mailto:blake.pokress@integrum.se)

### **Certified Adviser**

Erik Penser Bank AB, Certified Adviser can be reached at +46 8 463 8000 or [certifiedadviser@penser.se](mailto:certifiedadviser@penser.se)

### **About Integrum**

Integrum AB is a publicly traded company (INTEG B: Nasdaq First North exchange) based outside of Gothenburg, Sweden with a U.S. subsidiary in San Francisco, CA. Since 1990 osseointegration, the science behind the OPRA™ Implant System, has been helping individuals



with amputations towards an improved quality of life. A thorough surgical experience gained over two decades has led to development of Integrum's system for bone-anchored prosthetics – a beneficial alternative to the traditionally used socket prosthesis. Integrum is the worldwide scientific and thought leader in this area treating hundreds of patients from all parts of the world including clinical centers in the US. Integrum's OPRA™ Implant System was approved by the U.S. Food and Drug Administration (FDA) in 2015 for use in the US under a Humanitarian Use Device (HUD) designation which was reviewed through the Humanitarian Device Exemption (HDE) pathway. The OPRA™ Implant System is the only FDA-approved technology for bone-anchored prosthetics available in the US. More information on the company and its innovative solutions for amputees can be found at [www.integrum.se](http://www.integrum.se).